Hims & Hers Health announced a definitive agreement to acquire Boston‑based YourBio Health, a company that develops capillary whole‑blood sampling technology. The all‑cash transaction is expected to close in early 2026, subject to customary regulatory approvals and closing conditions.
The deal brings YourBio’s patented TAP® device and HALO™ microneedle platform into Hims & Hers’ portfolio, enabling a virtually painless, at‑home blood collection experience that could replace traditional fingerstick or venipuncture methods. This technology aligns with Hims & Hers’ strategy to expand its diagnostics arm, Labs, and to enhance the customer experience across its telehealth and prescription services.
Hims & Hers has recently posted strong financial results, with Q3 2025 revenue of $599.0 million, up 49% year‑over‑year, net income of $15.8 million, and adjusted EBITDA of $78.4 million. The company’s diagnostics business has grown rapidly, and the acquisition is expected to accelerate that growth trajectory.
CEO Andrew Dudum said the acquisition “represents a major advancement in user experience and design, and we’re excited to bring it into the Hims & Hers ecosystem.” YourBio’s CEO Paul Owen and Chief Scientific Officer Dr. Michael Mina will join Hims & Hers, bringing expertise in microneedle technology and a strong scientific team.
While the deal value was not disclosed, the all‑cash structure indicates Hims & Hers will use its robust balance sheet to fund the purchase. The transaction is expected to enhance customer engagement, reduce friction in sample collection, and differentiate Hims & Hers from competitors in the growing consumer health testing market.
The acquisition is part of a broader trend of Hims & Hers expanding its in‑house diagnostics capabilities, following the launch of Labs and the acquisition of Trybe Labs. Integrating YourBio’s technology is expected to strengthen the company’s competitive position and support long‑term growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.